Emerging drugs for Parkinson's disease

John C. Morgan, Kapil D. Sethi

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Parkinson's disease (PD) afflicts millions of people worldwide. There are numerous drugs available for PD; however, levodopa remains the gold standard of pharmacotherapy to which all other therapies are compared. Levodopa is quite effective for many motor symptoms (bradykinesia, tremor, rigidity) of PD; however, non-levodopa-responsive motor symptoms (postural instability) and nonmotor symptoms are frequently the most troublesome in middle and later stages of disease. Although motor symptoms remain an important focus for emerging drugs, current research is largely geared to identify and develop disease-slowing therapies. Another important area of focus has become treatment of the nonmotor symptoms of PD (especially depression and dementia). This review discusses emerging drugs in the management of the motor and nonmotor symptoms of PD and drugs under study as disease-slowing/neuroprotective agents.

Original languageEnglish (US)
Pages (from-to)403-417
Number of pages15
JournalExpert Opinion on Emerging Drugs
Issue number3
StatePublished - Sep 2006


  • ACP-103
  • Coenzyme Q
  • Creatine
  • Dementia
  • Depression
  • Donepezil
  • Dopamine agonist
  • Dyskinesias
  • GDNF
  • GPI-1485
  • Galantamine
  • Glutamic acid decarboxylase
  • MAO-B inhibitor
  • Memantine
  • Minocycline
  • Modafinil
  • Nefazodone
  • Neuroprotection
  • Neurturin
  • Paroxetine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Emerging drugs for Parkinson's disease'. Together they form a unique fingerprint.

Cite this